MUCOSAL IRON UPTAKE AND TRANSFER IN HEMOCHROMATOSIS

该项目的长期目标是开发一种非侵入性和准确的方法，用于测量非放射性（稳定）同位素标记的铁的粘膜吸收和转移，用于遗传性血色病（HHC）患者的一般用途。该方法基于摄入含有标记的（58 Fe）硫酸亚铁、不可吸收标记物氯化镝（DyCl 3）和视觉标记物FD-C#1（亮蓝）的单个明胶胶囊，然后通过分析一小部分第一次视觉标记的粪便中的标记铁和Dy来测量初始粘膜摄取。吸收的标记铁的全身保留是通过在循环红细胞中掺入摄取的同位素来测量的，或者在注射小剂量的57 Fe-转铁蛋白与口服剂量同时后1-3小时测量血浆中58 Fe/57 Fe的比率。拟议的第一阶段研究的具体目标是证明这种方法在10例单纯缺铁患者中的可行性。拟议的商业应用：这项研究将导致一种方法，用于血色素沉着症患者的常规使用。它在确定诊断，预测预后和血色病研究的许多方面都有应用。

The long-term objectives of this project are to develop a non-invasive and accurate method for the measurement of mucosal uptake and transfer of iron labeled with a non-radioactive (stable) isotope for general-purpose use with hereditary hemochromatosis (HHC) patients. The method is based on ingesting a single gelatin capsule containing labeled (58Fe) ferrous sulfate, the non-absorbable marker dysprosium chloride (DyCl3), and the visual marker FD&C#1 (brilliant blue) followed by the measurement of initial mucosal uptake by analysis of a small portion of the first visually marked stool for labeled iron and Dy. Whole-body retention of absorbed labeled iron is measured from either incorporation of the ingested isotope in circulating red cells, or measured of the ratio for 58Fe/57Fe in plasma 1-3 hours after injection of a small dose of 57 Fe- transferrin concurrently with the oral dose. The specific aims of the proposed phase-I research are to demonstrate the feasibility of this approach in ten patients with uncomplicated iron-deficiency. PROPOSED COMMERCIAL APPLICATIONS: This research will lead to a method for routine use in hemochromatosis patients. It has applications in confirming diagnosis, predicting prognosis, and many aspects of hemochromatosis research.